Global Pleuromutilin Supply, Demand and Key Producers, 2026-2032
Description
The global Pleuromutilin market size is expected to reach $ 140 million by 2032, rising at a market growth of 4.8% CAGR during the forecast period (2026-2032).
Pleuromutilin is a broad-spectrum diterpene antibiotic produced by Pleurotus mutilus. It is the precursor of semi-synthetic derivatives of pleuromutilin and can effectively inhibit most Gram-negative bacteria. positive bacteria and some Gram-negative bacteria. Pleuromutilin is a class of antibacterial substances that work by inhibiting the synthesis of protein in bacteria. Pleuromutilins were discovered in the 1950s mainly for veterinary purposes. Pleuromutilin is used for the treatment and prevention of gastrointestinal and respiratory infections caused by different bacterial pathogens in pigs, poultry and rabbits. In our report, our statistical standard is based on 100% content. Active Ingredient Contents is 100%.In 2025, global Pleuromutilin production reached approximately 2557 MT and price is about 38.5 USD/Kg.The average gross profit margin of this product is 13%.
Rising biosecurity expectations and the operational needs of large-scale farming are reinforcing “health management to protect production efficiency” as a durable spending driver. In this environment, clinically familiar pleuromutilin-class solutions remain strategically relevant in key swine respiratory and mycoplasma-related scenarios. In parallel, regulators are advancing prudent use, prescription control, and AMR-oriented oversight, pushing the industry away from extensive use toward standardized, compliant programs. This structural shift favors suppliers that can deliver consistency, registrations, and customer support through a robust compliance and quality system. The veterinary antibacterial segment faces multi-layer constraints: AMR governance tightens prescription compliance, indication boundaries, and intensity management; food safety and residue frameworks raise customer expectations for batch consistency, impurity control, and traceable documentation; and leading animal-health companies increasingly emphasize responsible use and portfolio mix evolution in their annual reporting—signaling a market where compliance execution and solution capability matter as much as price. Collectively, these forces elevate the integrated bar across registration, QA, and channel access. Demand is shifting from “treatment only” to “a component of farm management.” Producers increasingly seek test-informed, segmented medication, better course compliance, and closed-loop recording to reduce systemic outbreak risk. Meanwhile, the implementation of modern veterinary-medicine rules in markets such as the EU further strengthens requirements around prescription justification and process traceability, encouraging more standardized dosage forms and stronger service/tooling around compliant execution. Broker research commonly frames animal-health opportunity around scale-up, compliance upgrading, and substitution/upgrade dynamics—favoring suppliers with dependable delivery and governance-ready operating models. Upstream competitiveness is shaped less by “raw materials” alone and more by reproducible process control and auditable quality systems. For pleuromutilin derivatives, upstream typically spans fermentation-linked nucleus/intermediate sourcing, semi-synthetic reaction inputs (reagents/solvents), and controlled salt formation plus crystallization/purification steps. Veterinary GMP and regulatory expectations convert quality management, documentation, and on-site consistency into non-negotiable requirements, accelerating upstream consolidation toward compliant, scalable, audit-ready operations. In practice, sustainable advantage comes from high-yield scale-up, stable impurity profiles, continuous supply, and audit pass-rates—ultimately reinforcing brand trust and customer stickiness.
This report studies the global Pleuromutilin production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Pleuromutilin and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Pleuromutilin that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Pleuromutilin total production and demand, 2021-2032, (MT)
Global Pleuromutilin total production value, 2021-2032, (USD Million)
Global Pleuromutilin production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (MT), (based on production site)
Global Pleuromutilin consumption by region & country, CAGR, 2021-2032 & (MT)
U.S. VS China: Pleuromutilin domestic production, consumption, key domestic manufacturers and share
Global Pleuromutilin production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (MT)
Global Pleuromutilin production by Type, production, value, CAGR, 2021-2032, (USD Million) & (MT)
Global Pleuromutilin production by Application, production, value, CAGR, 2021-2032, (USD Million) & (MT)
This report profiles key players in the global Pleuromutilin market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sunny Biotech, Hebei Weiyuan, Shandong Shengli, Shandong Lukang, Qingdao Dierman, Qilu Pharma, Huvepharma, Novartis, Vethellas, Elanco, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Pleuromutilin market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (MT) and average price (US$/Kg) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Pleuromutilin Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Pleuromutilin Market, Segmentation by Type:
Premix
API Powder
Global Pleuromutilin Market, Segmentation by Salt Form:
Fumarates
Tartrates
Others
Global Pleuromutilin Market, Segmentation by Indication Cluster:
Respiratory
Digestiv
Other
Global Pleuromutilin Market, Segmentation by Application:
Livestock
Poultry
Companies Profiled:
Sunny Biotech
Hebei Weiyuan
Shandong Shengli
Shandong Lukang
Qingdao Dierman
Qilu Pharma
Huvepharma
Novartis
Vethellas
Elanco
Key Questions Answered:
1. How big is the global Pleuromutilin market?
2. What is the demand of the global Pleuromutilin market?
3. What is the year over year growth of the global Pleuromutilin market?
4. What is the production and production value of the global Pleuromutilin market?
5. Who are the key producers in the global Pleuromutilin market?
6. What are the growth factors driving the market demand?
Pleuromutilin is a broad-spectrum diterpene antibiotic produced by Pleurotus mutilus. It is the precursor of semi-synthetic derivatives of pleuromutilin and can effectively inhibit most Gram-negative bacteria. positive bacteria and some Gram-negative bacteria. Pleuromutilin is a class of antibacterial substances that work by inhibiting the synthesis of protein in bacteria. Pleuromutilins were discovered in the 1950s mainly for veterinary purposes. Pleuromutilin is used for the treatment and prevention of gastrointestinal and respiratory infections caused by different bacterial pathogens in pigs, poultry and rabbits. In our report, our statistical standard is based on 100% content. Active Ingredient Contents is 100%.In 2025, global Pleuromutilin production reached approximately 2557 MT and price is about 38.5 USD/Kg.The average gross profit margin of this product is 13%.
Rising biosecurity expectations and the operational needs of large-scale farming are reinforcing “health management to protect production efficiency” as a durable spending driver. In this environment, clinically familiar pleuromutilin-class solutions remain strategically relevant in key swine respiratory and mycoplasma-related scenarios. In parallel, regulators are advancing prudent use, prescription control, and AMR-oriented oversight, pushing the industry away from extensive use toward standardized, compliant programs. This structural shift favors suppliers that can deliver consistency, registrations, and customer support through a robust compliance and quality system. The veterinary antibacterial segment faces multi-layer constraints: AMR governance tightens prescription compliance, indication boundaries, and intensity management; food safety and residue frameworks raise customer expectations for batch consistency, impurity control, and traceable documentation; and leading animal-health companies increasingly emphasize responsible use and portfolio mix evolution in their annual reporting—signaling a market where compliance execution and solution capability matter as much as price. Collectively, these forces elevate the integrated bar across registration, QA, and channel access. Demand is shifting from “treatment only” to “a component of farm management.” Producers increasingly seek test-informed, segmented medication, better course compliance, and closed-loop recording to reduce systemic outbreak risk. Meanwhile, the implementation of modern veterinary-medicine rules in markets such as the EU further strengthens requirements around prescription justification and process traceability, encouraging more standardized dosage forms and stronger service/tooling around compliant execution. Broker research commonly frames animal-health opportunity around scale-up, compliance upgrading, and substitution/upgrade dynamics—favoring suppliers with dependable delivery and governance-ready operating models. Upstream competitiveness is shaped less by “raw materials” alone and more by reproducible process control and auditable quality systems. For pleuromutilin derivatives, upstream typically spans fermentation-linked nucleus/intermediate sourcing, semi-synthetic reaction inputs (reagents/solvents), and controlled salt formation plus crystallization/purification steps. Veterinary GMP and regulatory expectations convert quality management, documentation, and on-site consistency into non-negotiable requirements, accelerating upstream consolidation toward compliant, scalable, audit-ready operations. In practice, sustainable advantage comes from high-yield scale-up, stable impurity profiles, continuous supply, and audit pass-rates—ultimately reinforcing brand trust and customer stickiness.
This report studies the global Pleuromutilin production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Pleuromutilin and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Pleuromutilin that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Pleuromutilin total production and demand, 2021-2032, (MT)
Global Pleuromutilin total production value, 2021-2032, (USD Million)
Global Pleuromutilin production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (MT), (based on production site)
Global Pleuromutilin consumption by region & country, CAGR, 2021-2032 & (MT)
U.S. VS China: Pleuromutilin domestic production, consumption, key domestic manufacturers and share
Global Pleuromutilin production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (MT)
Global Pleuromutilin production by Type, production, value, CAGR, 2021-2032, (USD Million) & (MT)
Global Pleuromutilin production by Application, production, value, CAGR, 2021-2032, (USD Million) & (MT)
This report profiles key players in the global Pleuromutilin market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sunny Biotech, Hebei Weiyuan, Shandong Shengli, Shandong Lukang, Qingdao Dierman, Qilu Pharma, Huvepharma, Novartis, Vethellas, Elanco, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Pleuromutilin market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (MT) and average price (US$/Kg) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Pleuromutilin Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Pleuromutilin Market, Segmentation by Type:
Premix
API Powder
Global Pleuromutilin Market, Segmentation by Salt Form:
Fumarates
Tartrates
Others
Global Pleuromutilin Market, Segmentation by Indication Cluster:
Respiratory
Digestiv
Other
Global Pleuromutilin Market, Segmentation by Application:
Livestock
Poultry
Companies Profiled:
Sunny Biotech
Hebei Weiyuan
Shandong Shengli
Shandong Lukang
Qingdao Dierman
Qilu Pharma
Huvepharma
Novartis
Vethellas
Elanco
Key Questions Answered:
1. How big is the global Pleuromutilin market?
2. What is the demand of the global Pleuromutilin market?
3. What is the year over year growth of the global Pleuromutilin market?
4. What is the production and production value of the global Pleuromutilin market?
5. Who are the key producers in the global Pleuromutilin market?
6. What are the growth factors driving the market demand?
Table of Contents
114 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Manufacturers Competitive Analysis
- 4 United States VS China VS Rest of the World
- 5 Market Analysis by Type
- 6 Market Analysis by Salt Form
- 7 Market Analysis by Indication Cluster
- 8 Market Analysis by Application
- 9 Company Profiles
- 10 Industry Chain Analysis
- 11 Research Findings and Conclusion
- 12 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
